Adaptimmune Therapeutics plc (ADAP)
NASDAQ: ADAP · Real-Time Price · USD
0.708
-0.015 (-2.12%)
Dec 3, 2024, 12:14 PM EST - Market open
Adaptimmune Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for ADAP stock have an average target of 2.79, with a low estimate of 1.50 and a high estimate of 3.50. The average target predicts an increase of 294.18% from the current stock price of 0.71.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ADAP stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 1 | 1 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 3 | 3 | 3 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho | Mizuho | Buy Maintains $3 → $1.5 | Buy | Maintains | $3 → $1.5 | +111.92% | Nov 27, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $3.5 | Strong Buy | Reiterates | $3.5 | +394.49% | Nov 19, 2024 |
| Guggenheim | Guggenheim | Strong Buy Maintains $4 → $3 | Strong Buy | Maintains | $4 → $3 | +323.85% | Nov 15, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $4 → $3.5 | Strong Buy | Maintains | $4 → $3.5 | +394.49% | Nov 14, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +465.13% | Aug 13, 2024 |
Financial Forecast
Revenue This Year
177.62M
from 60.28M
Increased by 194.65%
Revenue Next Year
43.19M
from 177.62M
Decreased by -75.68%
EPS This Year
-0.18
from -0.57
EPS Next Year
-0.37
from -0.18
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 201.4M | 58.8M | 136.3M | |||
| Avg | 177.6M | 43.2M | 78.8M | |||
| Low | 145.9M | 26.8M | 50.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 234.1% | -66.9% | 215.5% | |||
| Avg | 194.7% | -75.7% | 82.5% | |||
| Low | 142.1% | -84.9% | 16.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -0.03 | -0.08 | -0.05 |
| Avg | -0.18 | -0.37 | -0.24 |
| Low | -0.55 | -0.58 | -0.49 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.